简介：AreviewarticlebyHaoetal.(JAmCollCardiol2017;69(24):2952–66)hashadhugerepercussionsamongthosefamiliarwithtraditionalChinesemedicine(TCM)intheinternationalacademiccommunity.ItevaluatedtheefficacyandsafetyofTCMforcardiovasculardiseaseandthepharmacologicaleffectofactiveTCMingredientsonthecardiovascularsystemandpotentialmechanisms.Wehaveseveralcomments:Firstly,wegiveabriefsummaryaddressingnonpharmacotherapyinTCM,includingacupuncture,moxibustion,Qigong,andTaiChi.Secondly,wehaveaddedtraditionalantiarrhythmicdrug–relatedrandomizedcontrolledtrialstomakethecoveragemorecomprehensive.Lastly,wesupporttheconceptthatresearchinto,developmentof,andapplicationofactiveingredientsispartofmodernTCM.

简介：Cardiovasculardisease(CVD)anddepressionandanxietycontributesubstantiallytothecurrentdiseaseburdenworldwideaswellasinChina.BothdepressionandanxietyarehighlyprevalentamongpatientswithCVD.WesystematicallyreviewedtheliteraturetodisentangletheroleofdepressionandanxietydisordersintheonsetandprognosisofCVDwithanemphasisoncohortstudiesconductedintheChinesepopulation.Despitethelackoflarge-scaleprospectivestudiesinChina,theavailableevidenceimpliesthatbothdepressionandanxietyarecloselyassociatedwiththeonsetandprognosisofCVD,includingischemicheartdiseaseandstroke,inChineseadults.Putativebehavioralandbiologicalmechanismsareimplicatedinthelinkbetweendepression/anxietyandCVD.TimelyscreeninganddiagnosisfollowedbypropertreatmentshouldbeimplementedfordepressionandanxietyinboththegeneralpopulationandpatientswithCVD.CurrentstandardtreatmentssuchasselectiveserotoninreuptakeinhibitorsandpsychotherapiesarerecommendedforCVDpatientswithdepression,althoughtheirefficacyforreducingCVDmorbidityandmortalityremainsuncertain.Inconclusion,prospectivestudiesonthelinkbetweendepression/anxietyandtheonsetandprognosisofCVDareurgentlyneededintheChinesepopulation,andmoreeffortsarewarrantedtoexaminetheefficacyofdepressionandanxietytreatmentsforCVDpatients,particularlytheintegratedcaremodelofincludingpsychiatristsinamultidisciplinaryclinicalgroup.

简介：Amlodipine/valsartan(Aml/Val)single-pillcombination(SPC)therapyhasbeenwidelyusedandstudiedinclinicalpracticeinrecentyears.ThisarticlereviewstheChineseandEnglishliteratureontheclinicaluseofAml/ValSPCtherapyinChinesehypertensivepatients.Accordingtofivestudiesconcerningtheefficacyandsafetyofthistreatment,Aml/ValSPCtherapywasmoreefficaciousthanmonotherapywithvalsartan,amlodipine,orthenifedipinegastrointestinaltherapeuticsystem.Thistreatmentshowedgreaterbloodpressure-loweringeffects,ahigherbloodpressurecontrolrate,andahigherresponserate.Aml/ValSPCtreatmentwaswelltolerated,withadverseeventratessimilartothoseofmonotherapywithvalsartanoramlodipineandsignificantlyrareradverseeventscomparedwiththenifedipinegastrointestinaltherapeuticsystem.Aml/ValSPCisahighlyefficaciousandwell-toleratedantihypertensivetreatmentinChinesehypertensivepatients.

简介：BackgroundApolipoprotein(apo)A-Visanovelmemberoftheapolipoproteinclusterinvolvedintriacylglycerol(TG)homeostasis.IthasreportedthatAPOA5genepolymorphismsiscorrelatedwitharterioscleroticdiseases.However,ThisassociationisunknownonChinesepatientswithatheroscleroticcerebralinfarction.ThepresentstudyaimedtoelucidatetherelationshipofAPOA5-1131T>Candarterioscleroticcerebralinfarction(ACI)aswellasthelevelsofserumlipids.MethodsPolymerasechainreaction-restrictionfragmentslengthpolymorphisms(PCR-RFLP)analysis,enzymaticandimmunoturbidimetrymethodswereusedtomeasure-1131T>Cgenotype,allelefrequencyaswellasplasmalipidlevelof90ACIpatientsand221healthysubjectsofHanChinese.ResultsInACIgroup,thelevelofTGinalleleCcarrierswashigherthanthatofnon-Ccarriers(P<0.05).ThefrequencyofalleleCinACIgroupwashigherthaninhealthygroup(χ~2=5.568,P=0.018).Exceptsex,ageandBMI,thelevelsoftotalcholesterol(TC),triglycerides(TG),highdensitylipoproteincholesterol(HDL-C),low-densitylipoproteincholesterol(LDL-C),APOA1andAPOBinACIgroupdistinctivelywerehigherthanthoseinhealthygroup.ConclusionTheAPOA5-1131alleleCisassociatedwiththehighlevelofTGinACIpatients,whichisprobablylinkedwithACIdangerofChineseHan.

简介：Complicationsaremorefrequentinelderlypatientswithcoronaryheartdisease(CHD),suchasimpairedglucosetoleranceandconstipations.Itisalwaysdifficulttocurethesecomplicationsinclinicalpractice.Inthiscasewehadsuccessfullycuredaneighty-threeyearsoldmanwithCHDcomplicatingimpairedglucosetoleranceandconstipationbyintegratedChinese-Westernmedicine.

简介：Objective:Therandomizedcontrolledtrial(ClinicalTrials.govidentifierNCT02990741)willinvestigatewhethermorefrequentelectrocardiographic(ECG)recordingsandanalyseswithanautomatedECGsystemwouldimprovedetectionofatrialfibrillationcomparedwithasingleannualECGscreeninelderlyChineseincommunityhealthcenters.Design:Menandwomen(≥65years)willberandomizedintointensive(n=3500)andusual(n=3500)screeninggroups,andwithintheintensivescreeninggroupintointensivescreening(n=2625)andmoreintensivescreening(n=875)subgroups.ECGrecordingswillbeperformedwithanautomatedECGanalysissystem(AliveCorheartmonitor)at1yearintheusualscreeninggroup,at3,6,9,and12monthsintheintensivescreeningsubgroup,andat1,2,3,and4weeksand3,6,9,and12monthsinthemoreintensivescreeningsubgroup.Theprimaryoutcomeisthedetectionrateofatrialfibrillationbetweentheusualscreeninggroupandtheintensivescreeninggroup.Samplesizeestimationwasbasedonaprojecteddetectionrateofatrialfibrillationof2.0%byasingleECGrecordingat12months,animprovementof50%withmorefrequentECGrecordings,α=0.05,powerof80%,andaone-sidedtest.Conclusions:ThetrialwillprovideevidenceontheclinicaleffectivenessofmorefrequentECGrecordingsbyahandheldautomatedanalysissysteminthedetectionofatrialfibrillation.